The Biologic Clinical Design Alignment Model for Therapeutic Drug Development

Why do promising drugs fail despite compelling science?

The Biologic-Clinical-Design Alignment Model for Therapeutic Drug Development presents a practical framework for understanding why scientifically promising therapies may fail to produce meaningful clinical benefit.

The book introduces three interconnected pillars-Biologic Alignment, Clinical Alignment, and Design Alignment-and explores how successful drug development depends on matching the right therapeutic mechanism to the right patients, clinical setting, and trial design.

Drawing extensively from oncology and hematologic malignancies, it examines therapeutic dependencies, biomarkers, resistance, patient selection, benefit-risk, combination strategies, clinical endpoints, and trial success and failure.

Written for drug developers, clinical investigators, translational scientists, regulatory professionals, biotechnology leaders, investors, and advanced trainees, the book provides a structured approach to translating promising science into meaningful patient benefit.

The central message is simple: successful drug development requires alignment between mechanism, medicine, and trial design.